Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL442864 | 0.99 | KMT2A (0.43) | KMT2AMAPK1AKR1B1SMN1; SMN2HPGD | |
| SCHEMBL405856 | 0.94 | MAPK1 (0.43) | KMT2AMAPK1AKR1B1SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL443165 | 0.93 | MAPK1 (0.42) | KMT2AMAPK1AKR1B1SMN1; SMN2HPGD | |
| SCHEMBL405978 | 0.92 | EPHX2 (0.42) | KMT2AMAPK1SMN1; SMN2HPGDALDH1A1 | |
| Etiguanfacine SCHEMBL406264 | 0.91 | ALDH1A1 (0.48) | KMT2AMAPK1AKR1B1SMN1; SMN2ALDH1A1 | |
| Etiguanfacine SCHEMBL440827 | 0.90 | ALDH1A1 (0.47) | KMT2AMAPK1AKR1B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL406863 | 0.90 | KMT2A (0.43) | KMT2AMAPK1AKR1B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL406853 | 0.87 | KMT2A (0.42) | KMT2AMAPK1AKR1B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL406768 | 0.86 | MAPK1 (0.43) | KMT2AMAPK1AKR1B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL405981 | 0.86 | MAPK1 (0.44) | KMT2AMAPK1AKR1B1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012035346-A1 | PRODRUGS OF GUANFACINE | SHIRE, LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | UGT1A6, GDA, UGT1A3 | KMT2A 1095/4885MAPK1 4054/4885AKR1B1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.